Engagement of the OX-40 receptor in vivo enhances antitumor immunity

Journal of Immunology

Volumn 164, Issue 4, 2000, Pages 2160-2169

  Weinberg, Andrew D ^a   Rivera, Martin Muy ^a   Prell, Rodney ^a   Morris, Arden ^b   Ramstad, Trygg ^a   Vetto, John T ^b   Urba, Walter J ^a   Alvord, Gregory ^c   Bunce, Campbell ^d   Shields, John ^d  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034651736     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.4.2160     Document Type: Article

References (55)

1. Chen, L. P., S. Ashe, W. Brady, L. Hellstrom, K. Hellstrom, J. Ledbetter, P. McGowan, and P. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093.
2. + T cells by B7-transfected melanoma cells. Science 259:368.
3. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. Nadler, G. Freeman, and L. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc. Natl. Acad. Sci. USA 90:5687.
4. + tumor cells are potent vaccines for stimulation tumor rejection in tumor-bearing mice. J. Exp. Med. 181:619.
5. Chen, L., P. McGowan, S. Ashe, S. Johnston, Y. Li, L. Hellstrom, and K. Hellstrom. 1994 Tumor immunogenicity determines the effect of B7 costimulation on T cell mediated immunity. J. Exp. Med. 179:523.
6. Baskar, S., V. K. Clements, L. H. Glimcher, N. Nabavi, and S. Ostrand-Rosenberg. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156: 3821.
7. + MHC class II-restricted T cells that are cytolytic and tumoricidal in vivo. J. Immunol. 154:4613.
8. Melero, I., W. W. Shuford, S. Ashe, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T cell activation molecule eradicates established tumors. Nat. Med. 3:682.
9. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. Deleo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
10. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297.
11. Nagata, Y., R. Furugen, A. Hiasa, H. Ikeda, N. Ohta, K. Furukawa, H. Nakamura, K. Furukawa, T. Kanematsu, and H. Shiku. 1997. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol. 159:1336.
12. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160:3444.
13. Hintzen, R. Q., R. de Jong, S. M. A. Lens, and R. A. W. van Lier. 1994. CD27: marker and mediator of T-cell activation? Immunol. Today 15:307.
14. Callard, R., R. J. Armitage, W. C. Fanslow, and M. K. Spriggs. 1993. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14:559.
15. Mayawaki, T., T. Uehara, R. Nibu, T. Tsuji, A. Yachie, S. Yonehara, and N. Taniguchi. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149:3753.
16. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
17. r detected only on CD4 positive T blasts. Mol. Immunol. 24:1281.
18. lax. Mol. Cell. Biol. 11:1313.
19. Stuber, E., M. Neurath, D. Calderhead, H.P. Fell, and W. Strober. 1995. Crosslinking of OX-40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507.
20. Imura, A., T. Hori, K. Imada, T. Ishikawa, Y. Tanaka, M. Maeda, S. Imamura, and T. Uchiyama. 1996. The human OX-40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183:2185.
21. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Ann. Rev. Immunol. 14:233.
22. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
23. Gramaglia, I., A. D. Weinberg, M. Lemon, and M. Croft. 1998. OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 161:6510.
24. Weinberg, A. D., A. T. Vella, and M. Croft. 1998. OX-40: life beyond the effector T cell stage. Semin. Immunol. 10:471.
25. Weinberg, A. D., J. J. Wallin, R. E. Jones, T. J. Sullivan, D. N. Bourdette, A. A. Vandenbark, and H. Offner. 1994. Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J. Immunol. 152:4712.
26. Weinberg, A. D., D. N. Bourdette, T. J. Sullivan, M. Lemon, J. J. Wallin, F. Palida, R. J. Fulton, H. Offner, and A. A. Vandenbark. 1996. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. 2:183.
27. + T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J. Neurosci. Res. 43:42.
28. + spinal cord T cells of Lewis rats with EAE. J. Neurosci. Res. 44:562.
29. Vetto, J. T., S. Lum, A. Morris, M. Sicotte, J. Davis, M. Lemon, and A. Weinberg. 1997. Presence of the T cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head neck cancers. Am. J. Surg. 174:258.
30. Hart, I. R. 1979. The selection and characterization of an invasive variant of the B16 melanoma. Am. J. Pathol. 9:587.
31. Area, M. J., J. C. Krauss, A. Aurga, M. J. Cameron, S. Shu, and A. E. Chang. 1996. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete GMCSF. Cancer Gene Ther. 3:39.
32. Huntzicker, E. G., and B. A. Fox. 1995. Characterization of thirteen new methylcolanthrene induced murine sarcomas. Ninth International Congress of Immunology. San Francisco. Abst. 5170:872.
33. Guzman, R. C., R. O. Osborn, M. N. Swanson, R. Sakthivel, S.-I. Hwang, S. Miyamoto, and S. Nandi. 1992. Incidence of c-Ki-ras activation in N-methyl-N-nitrosourea-induced mammary carcinomas in pituitary-isografted mice. Cancer Res. 52:5732.
34. Brattain, M. G., J. Strobel-Stevens, D. Fine, M. Webb, and A. M. Sarrif, 1980. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 40:2142.
35. Sonouchi, K., T. A., Hamilton, C. S. Tannenbaum, R. R., Tubbs, R., Bukowski, and J. H. Finke. 1994. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with IFN-α and IL-2. Am. J. Pathol. 4:747.
36. Crowe, P. D., T. L. Van Arsdale, B. N. Walter, C. F. Ware, C. Hession, B. Ehrenfels, J. L. Browning, W. S. Din, R. G. Goodwin, and C. A. Smith. 1994. A lymphotoxin-β-specific receptor. Science 264:707.
37. Al-Shamkhani, A., M. L. Birkeland, M. Puklavec, M. H. Brown, W. James, and A. N. Barclay. 1996. OX-40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX-40 ligand. Eur. J. Immunol. 26:1695.
38. Shi, S. R., M. E. Key, and K. L. Kalra. 1991. Antigen retrieval in Formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 39:741.
39. + T cells. Int. Immunol. 10:453.
40. Flynn, S., K. M., Toellner, C., Raykundalia, M., Goodall, and P. Lane. 1998. CD4 T cell cytokine differentiation: the B cell molecule, OX-40 ligand, instructs CD4 T cells to express IL-4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297.
41. + T cells into high IL-4-producing effectors. Blood 92:3338.
42. Baum, P. R., R. B. Gayle, F. Ramsdell, S. Srinivasan, R. A. Sorensen, M. L. Watson, M. F. Seldin, E. Baker, G. R. Sutherland, K. N. Clifford, et al. 1994. Molecular characterization of murine and human OX-40/OX-40 ligand systems: identification of a human OX-40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 13:3992.
43. Hurwitz, A. A., T. F. Yu, D. R. Leach, and J. P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived GMCSF for treatment of an experimental mammary carcinoma. Pro. Natl. Acad Sci. USA 95:10067.
44. Vinay, D. S., and B. S. Kwon. 1998. Role of 4-1BB in immune responses. Semin. Immunol. 10:481.
45. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47.
46. Zhang, X., T. Brunner, L. Carter, R. W. Dutton, P. Rogers, L. Bradley, T. Sato, J. Reed, D. Green, and S. L. Swain. 1997. Unequal death in T helper cell Th1 and Th2 effectors: Th1, but not Th2 effectors undergo rapid Fas:FasL mediated apoptosis. J. Exp. Med 185:1837.
47. Maxwell, J., A. D. Weinberg, R. A. Prell, and A. T. Vella. 2000. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immuol. 164:107.
48. + T cells persist in vivo following induction of peripheral tolerance. J. Immunol. 160:4719.
49. Litton, M. J., B. Sander, E. Murphy, A. O'Garra, and J. S. Abrams. 1994. Early expression of cytokines in lymph nodes after treatment in vivo with SEB. J. Immunol. Methods 175:47.
50. Hu, H.-M., W. J. Urba, and B. A. Fox. 1998. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161:3033.
51. + T cells in the antitumor immune response. J. Exp. Med. 188:2357.
52. Ohshima, Y., Y. Tanaka, H. Tozawa, Y. Takahashi, C. Maliszewski, and G. Delespesse. 1997. Expression and function of OX-40 ligand on human dendritic cells. J. Immunol. 159:3838.
53. Weinberg, A. D., K. W. Wegmann, C. Funatake, and R. H. Whitham. 1998. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of EAE. J. Immunol. 162:1818.
54. Chouaib, S., C Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493.
55. Miller, F. R., B. E. Miller, and G. H. Heppner. 1993. Tumour Immunobiology: Assessment of the Immunogenicity of Tumour Models. G. Gallagher, R. C. Rees, and C. W. Reynolds, eds. Oxford Univ. Press. New York, pp 17-26.